Database

Startups

Main Industry
Health Care
Main Product/Service
PapiVax’s product pipeline focuses on therapeutic vaccines against HPV infection and related cancers (e.g. cervical, head‑and‑neck cancers), with several candidates such as PVX‑4, PVX‑7, and PVX‑8 already in clinical‑trial stages; the company also offers
Founded Year
2025
Unified Business No.
96819818
Status
Active
Number of Employees
0
Total Paid-in Capital
610,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
PapiVax Biotech, Inc., founded in 2013 and headquartered in Taipei with a subsidiary in the United States, is a biotech company specializing in nucleic‑acid immunotherapy using proprietary DNA‑plasmid vector and delivery platforms — aiming to become a glo



More ↓

Similar Companies